Introduction: DSMES is a critical component of diabetes (DM) care. Providers are expected to perform this service, but time for it is limited, especially for ongoing support. Digital tools, like mobile applications (apps) , show promise in extending efforts and supporting self-management, but have yet to be fully utilized. The purpose of this study was to examine provider insights on the role of mobile apps in DSMES delivery.

Methods: DM providers representing inpatient, outpatient, and community settings were invited to complete a validated survey about experiences with and perspectives on app use for DSMES. Survey results were recorded and summarized to capture dominant themes.

Results: Sixty providers (33% diabetes care and education specialists, DCESs, 21% endocrine clinicians) completed the survey. Of those, 17% (10/59) reported being very familiar with apps; 33% (20/59) had used an app to provide DM education while 25% (15/59) used an app for support. Respondents (77%, 46/60) primarily viewed apps as adjunct to DCES education, particularly for reinforcement. In terms of recommending apps, 90% of providers (54/60) rated patient app interest and access as most important factors to consider. In addition, 70% (42/60) agreed apps may be particularly useful to patients who use telehealth or live far from clinics. Specific to insulin, 70% agreed apps could serve as a helpful tool to prepare those new to insulin and aid with injection skills, dosing decisions and titration. Features they viewed as useful include clear set-up instructions, goal setting and digital coaching. Interestingly, outpatient DCESs reported willingness to use 15 or more minutes of visit on setting up/teaching app use, while hospital-based providers were willing to spend 5 minutes.

Conclusion: National standards recommend digital coaching as an effective method to deliver DSMES. These findings offer important feedback for introducing digital tools into clinical practice.

Disclosure

N.Mehrotra: None. J.S.Krall: Research Support; Becton, Dickinson and Company, Sanofi. J.Ng: Research Support; Sanofi. L.M.Siminerio: Advisory Panel; Abbott, Bayer AG, Research Support; Becton, Dickinson and Company, Sanofi.

Funding

Becton, Dickinson and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.